**Robust IPO activity continues into late 2026, supported by a steady pipeline of filings and pricings amid selective investor demand.** As of early November, 264 U.S. IPOs have priced year-to-date, with recent deals including multiple biotechs such as Aspen Neuroscience and Bambusa Therapeutics alongside fintech OPay. Anthropic’s S-1 filing late last month positions a potential record-sized offering for mid-November pricing, following SpaceX’s earlier large transaction that boosted year totals. Elevated Treasury yields near 5.2% and equity volatility have introduced selectivity, particularly for growth-oriented issuers, while AI-adjacent and healthcare sectors show relative strength. Additional SPAC and smaller operating-company deals remain scheduled, with the broader market environment shaped by earnings trends and monetary policy expectations ahead of year-end.